China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian…
BeiGene, Ltd. a global biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that its PARP inhibitor pamiparib has received…
Read More...
Read More...
